Douglas Scherr, MD
Urology · New York, NYNPI 1114014206
Payments from drug & device makers
Across 60 payments — averaging $1350.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogen Pharma, Inc.$59K
- Artivion, Inc.$13K
- Intuitive Surgical$7K
- Astrazeneca UK Limited$1K
- Ferring Pharmaceuticals Inc.$170
- Pfizer$167
- plus $522 from 7 others
Across 1 payment — averaging $352.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Urogen Pharma, Inc.$352
What the payments were for
- Consulting fees$1,07411%
- Travel & lodging$1,51016%
- Food & beverage$1,44415%
- Education$5,50058%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogen Pharma, Inc. | 29 | $58,949 |
| Artivion, Inc. | 3 | $12,831 |
| Intuitive Surgical | 12 | $7,334 |
| Astrazeneca UK Limited | 1 | $1,074 |
| Ferring Pharmaceuticals Inc. | 5 | $170 |
| Pfizer | 2 | $167 |
| Telix Pharmaceuticals | 1 | $166 |
| EDAP Technomed Inc | 1 | $121 |
| Astellas Pharma US Inc | 1 | $94 |
| Janssen Scientific Affairs, LLC | 1 | $45 |
| Johnson & Johnson | 1 | $34 |
| Coloplast | 1 | $32 |
| Immunitybio, Inc. | 2 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,759
- DA VINCI SP$1,500
- ILLUCCIX$331
- XTANDI$135
How this compares
$81,047 in reported general payments places this provider in the 90th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciprofloxacin Hcl | 461 | $1,186 |
| Tamsulosin Hcl | 61 | $764 |
| Tadalafil | 13 | $751 |
| Finasteride | 27 | $571 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 50 | $172 |
| Furosemide | 12 | $35 |
Paid to pharmacies, not to this prescriber.
Other urology in New York
- Guarionex DecastroNew York$5.7M
- James McKiernanNew York$4.1M
- William HuangNew York$3.9M
- Ashutosh TewariNew York$2.5M
- Bilal ChughtaiNew York$1.5M
- Nils Peter WiklundNew York$1M
- Herbert LeporNew York$823K
- Christopher AndersonNew York$785K
- Katie MurrayNew York$776K
- John SfakianosNew York$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.